[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-451168-105":59,"doc-detail-451168-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adrenal-suppression-in-duchenne-muscular-dystrophy-management-strategies-incorporating-novel-steroid-vamorolone","Adrenal Suppression in Duchenne Muscular Dystrophy - Management Strategies Incorporating Novel Steroid Vamorolone","","Perspective addressing adrenal suppression in Duchenne muscular dystrophy, outlining clinical management considerations and emphasizing mitigation strategies when using glucocorticoid therapy. The article highlights the need for vigilant assessment of adrenal function, individualized risk evaluation, and practical approaches to monitoring and adjusting treatment to balance benefits and endocrine safety. It incorporates discussion of vamorolone, a novel steroid option, and positions it within broader care optimization for affected patients and clinicians. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adrenal-suppression-in-duchenne-muscular-dystrophy-management-strategies-incorporating-novel-steroid-vamorolone/451168/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adrenal-suppression-in-duchenne-muscular-dystrophy-management-strategies-incorporating-novel-steroid-vamorolone/451168.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the focus of the article on adrenal suppression in Duchenne muscular dystrophy?","Question",{"text":112,"@type":113},"The article focuses on adrenal suppression and management strategies in Duchenne muscular dystrophy, including how to mitigate endocrine risks during steroid treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the article approach management strategies for glucocorticoid-related adrenal suppression?",{"text":117,"@type":113},"It emphasizes the need for careful assessment and monitoring of adrenal function and tailoring management to balance treatment effectiveness with endocrine safety.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does vamorolone play in the discussed management strategies?",{"text":121,"@type":113},"The article incorporates vamorolone as a novel steroid option within the overall framework of optimizing management for patients with Duchenne muscular dystrophy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},451168,1790795175,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of the Endocrine Society, 2026, 10, bvaf181 [https://doi.org/10.1210/jendso/bvaf181](https://doi.org/10.1210/jendso/bvaf181)  \nAdvance access publication 27 November 2025 Perspective  \nAdrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone  \nAnne Marie Sbrocchi, 1 Kathi Kinnett,2 Maria-Elena Lautatzis,3 Hugh J. McMillan,4  \nKathryn A. Selby,5 Aravind Veerapandiyan,6 David R. Weber,7,8 Susan Apkon,9  \nDiana X. Bharucha-Goebel, 10, 11 Sonum Bharill, 12 Shipra Bansal,6 Paula R. Clemens, 13, 14 Melissa Fiscaletti, 15 Rana Halloun, 16 Carol Lam, 17 Nadia Merchant, 18 Laura McAdam, 19 Nat Nasomyont,20 Stefan Nicolau,21 Maria F. Ochoa Molina,22 Kim Phung,23,24  \nMeilan M. Rutter,20 Mena Scavina,25 Prasanth N. Surampudi,26 Jaclyn Tamaroff,27 Cuixia Tian,28 Leanne M. Ward,23,24 Claire L. Wood,29 SzeChoong Wong,30,31 and Alex Ahmet23,24on behalf of The OPTIMIZE DMD Consortium  \n1 Division of Pediatric Endocrinology and Metabolism, Montreal Children’s Hospital, McGill University, Montreal, QC H4A 3J1, Canada 2 Parent Project Muscular Dystrophy (PPMD), Washington, DC 20005, USA  \n3 Division of Pediatric Endocrinology, Department of Pediatrics and Child Health, Manitoba Children’s Hospital, University of Manitoba, Winnipeg, MB R3B 0L8, Canada  \n4 Division of Neurology, Department of Pediatrics, Children’s Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, ON K1H 8L1, Canada  \n5 Division of Neurology, Department of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, BC V6H 3V4, Canada 6 Department of Pediatrics, Arkansas Children’s Hospital, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 7 Division of Endocrinology and Diabetes, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA  \n8 Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 04046, USA  \n9 Department of Physical Medicine and Rehabilitation, Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, CO 80262, USA  \n10Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH 43205, USA  \n11 Department of Pediatrics and Neurology, The Ohio State University, Columbus, OH 43210, USA  \n12 Division of Endocrinology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21211, USA 13 Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA  \n14 Neurology Service, Department of Veterans Affairs Medical Center, Pittsburgh, PA 15213, USA  \n15 Department of Pediatrics, Sainte Justine University Hospital, Université de Montréal, Montreal, QC H3T 1J4, Canada  \n16The Ottawa Pediatric Bone Health Research Group, Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada  \n17 Division of Endocrinology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada 18 Division of Pediatric Endocrinology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 19 Department of Pediatrics, Holland Bloorview Kids Rehabilitation Hospital, University of Toronto, Toronto, ON M4G 1R8, Canada 20 Division of Diabetes and Endocrinology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA  \n21Center for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH 43215, USA 22Endocrinology Unit, Division of Pediatrics, School of Medicine, Pontifical Catholic University of Chile, Marcoleta, Santiago 340, Chile 23 Division of Endocrinology, Children’s Hospital of Eastern Ontario (CHEO), Ottawa, ON K1H 8L1, Canada  \n24 Department of Pediatrics, University of Ottawa, Ottawa, ON K1H 8M5, Canada  \n25 Division of Neurology, Nemours Children’s Ho","cbCaihSXA5fEn9lt","https://ap.wps.com/l/cbCaihSXA5fEn9lt","pdf",330090,"English","# Adrenal Suppression in Duchenne Muscular Dystrophy\n## Management Strategies\n## Novel Steroid Vamorolone","[{\"question\":\"What is the focus of the article on adrenal suppression in Duchenne muscular dystrophy?\",\"answer\":\"The article focuses on adrenal suppression and management strategies in Duchenne muscular dystrophy, including how to mitigate endocrine risks during steroid treatment.\"},{\"question\":\"How does the article approach management strategies for glucocorticoid-related adrenal suppression?\",\"answer\":\"It emphasizes the need for careful assessment and monitoring of adrenal function and tailoring management to balance treatment effectiveness with endocrine safety.\"},{\"question\":\"What role does vamorolone play in the discussed management strategies?\",\"answer\":\"The article incorporates vamorolone as a novel steroid option within the overall framework of optimizing management for patients with Duchenne muscular dystrophy.\"}]","Adrenal Suppression in Duchenne Muscular Dystrophy - Management Strategies Incorporating Novel Steroid Vamorolone | PDF",1790734527]